Date: 2017-05-03
Type of
information: Treatment of the first patient
phase: 1-2
Announcement: treatment of the first patient
Company: Rigontec (Germany)
Product: RGT100
Action
mechanism:
- immunotherapy product. RGT100 targets the retinoic acid-inducible gene I (RIG-I) pathway, one of the most essential pathways in the innate immune system to induce both immediate and long-term anti-tumor immunity.
Disease: solid tumors, lymphoma
Therapeutic
area: Cancer - Oncology
Country: France, Germany, Spain, UK
Trial
details:
- The first-in-human study of a RIG-I agonist is designed to assess safety, tolerability and pharmacokinetics of RGT100 in patients with injectable solid tumor lesions. The multi-center study is conducted in immuno-oncology experienced centers in the United Kingdom, Spain, France and Germany and will include a dose-escalation part as well as several expansion arms. (NCT03065023)
Latest
news:
- • On May 3, 2017, Rigontec announced the dosing of the first patient in a phase I/II study with intratumoral/intralesional administration of its lead compound RGT100 in solid tumors and lymphoma. This product targets the retinoic acid-inducible gene I (RIG-I) pathway, one of the most essential pathways in the innate immune system to induce both immediate and long-term anti-tumor immunity. Targeting RIG-I is a novel and distinct approach in cancer immuno-therapy which has demonstrated substantial local and systemic tumor regression in several relevant in vivo models. This study will be the first to test the approach in patients.
Is
general: Yes
